Gene therapy for inherited retinal diseases: exploiting new tools in genome editing and nanotechnology
Open accessThe DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Abstract
Inherited retinal diseases (IRDs) encompass a diverse group of genetic disorders that lead to progressive visual impairment and blindness. Over the years, considerable strides have been made in understanding the underlying molecular mechanisms of IRDs, laying the foundation for novel therapeutic interventions. Gene therapy has emerged as a compelling approach for treating IRDs, with notable advancements achieved through targeted gene augmentation. However, several setbacks and limitations persist, hindering the widespread clinical success of gene therapy for IRDs. One promising avenue of research is the development of new genome editing tools. Cutting-edge technologies such as CRISPR-Cas9 nucleases, base editing and prime editing provide unprecedented precision and efficiency in targeted gene manipulation, offering the potential to overcome existing challenges in gene therapy for IRDs. Furthermore, traditional gene therapy encounters a significant challenge due to immune responses to viral vectors, which remain crucial obstacles in achieving long-lasting therapeutic effects. Nanotechnology has emerged as a valuable ally in the quest to optimize gene therapy outcomes for ocular diseases. Nanoparticles engineered with nanoscale precision offer improved gene delivery to specific retinal cells, allowing for enhanced targeting and reduced immunogenicity. In this review, we discuss recent advancements in gene therapy for IRDs and explore the setbacks that have been encountered in clinical trials. We highlight the technological advances in genome editing for the treatment of IRDs and how integrating nanotechnology into gene delivery strategies could enhance the safety and efficacy of gene therapy, ultimately offering hope for patients with IRDs and potentially paving the way for similar advancements in other ocular disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Modulation of surface characteris tics may help to improve transduction and reduce the dose required, thereby reducing the risk of GTAU (Mendes et al., 2022; Carvalho et al., 2023).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Carvalho et al., 2023
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133 · cited 1×
“In contrast, HDR uses a donor DNA template to install a desired sequence at a speci fi c site, resulting in a more precise product (14).”
MethodProgrammable editing of a target base in genomic DNA without double-stranded DNA cleavage
Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016) · Nature · doi:10.1038/nature17946 · Cited by 5,437
Search-and-replace genome editing without double-strand breaks or donor DNA
Anzalone, A. V., Randolph, P. B., Davis, J. R., Sousa, A. A., Koblan, L. W., Levy, J. M., Chen, P. J., Wilson, C., Newby, G. A., Raguram, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1711-4 · Cited by 4,767 · cited 2×
“Prime editors are the latest addition to the CRISPR/Cas toolbox (54) and consist of two main components: (1) a Cas nickase fused to a modi fi ed reverse transcriptase and (2) a prime editing gRNA (pegRNA) (Figure 1).”
BackgroundProgrammable base editing of A•T to G•C in genomic DNA without DNA cleavage
Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017) · Nature · doi:10.1038/nature24644 · Cited by 4,184
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Kosicki, M., Tomberg, K., & Bradley, A. (2018) · Nature Biotechnology · doi:10.1038/nbt.4192 · Cited by 1,883 · cited 1×
“…this problem, an increasing number of reports have disclosed several adverse consequences associated with the generation of DSBs in genomic DNA, including large deletions (31, 32), chromosomal rearrangements (33, 34), chromothripsis (35), viral integration (36), and activation of p53 (37, 38).”
BackgroundCRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
Regulation of Homologous Recombination in Eukaryotes
Heyer, W.-D., Ehmsen, K. T., & Liu, J. (2010) · Annual Review of Genetics · doi:10.1146/annurev-genet-051710-150955 · Cited by 1,066
Effect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029 · cited 1×
“Besides immunogenicity, another long-standing challenge facing AAVs is their limited cargo capacity ( 5 kb) (65), which hinders the packaging of large transgenes required for CRISPR-based genome editing tools.”
Background
Research works printed but not linked: 1
- 2022, Editas medicine announces clinical data demonstrating proof of concept of EDIT-101 from phase 1/2 BRILLIANCE trial [press release]
Cited by
Rowe, L. W., & Ciulla, T. A. (2024) · Genes · doi:10.3390/genes15060720 · Cited by 53
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
“Modulation of surface characteristics may help to improve transduction and reduce the dose required, thereby reducing the risk of GTAU (Mendes et al., 2022; Carvalho et al., 2023).”
Panferov, E., Dodina, M., Reshetnikov, V. V., Ryapolova, A., Ivanov, R. A., Karabelsky, A. V., & Minskaia, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125617 · Cited by 28
Chen, K.-S., Chan, H.-C., & Chan, C.-M. (2025) · Drugs · doi:10.1007/s40265-025-02237-2 · Cited by 27
“Base editing has been applied successfully in animal models of RPE65 mutations, demonstrating restored visual function with minimal off-target effects [61].”
Baig, M. M. F. A., Chien, W. T., & Chair, S. Y. (2025) · Biomaterials Science · doi:10.1039/d5bm00711a · Cited by 21
Metadata
- Authors
- Carvalho, C., Lemos, L., Antas, P., & Seabra, M. C.
- Affiliations
- Universidade Nova de Lisboa (PT)
- Champalimaud Foundation (PT)
- Corresponding author
- Antas, Pedro
- Seabra, Miguel C.
- Venue
- Frontiers in Ophthalmology
- Publisher
- Frontiers Media SA
- Published
- 2023-09-19
- Volume
- 3
- Pages
- 1270561-1270561
- ISSN
- 2674-0826 (ISSN-L)
- PMC
- PMC11182192
- OpenAlex
- W4386895570
- Cited by
- 21
- References
- 84
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 6
- FWCI
- 0.55
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Ophthalmology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- Funders
- Fundação Champalimaud
- Fundação para a Ciência e a Tecnologia (EXPL/MED-OUT/0599/2021, CEECIND/03862/2020)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- inherited retinal disease, gene therapy, genome editing, CRISPR/Cas9, base editing, prime editing, nanoparticle-mediated gene delivery, ocular gene therapy, blindness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gene therapy for inherited retinal diseases: exploiting new tools in genome editing and nanotechnology. https://app.cochat.ai/papers/10.3389/fopht.2023.1270561
- The paper
- Carvalho, C., Lemos, L., Antas, P., & Seabra, M. C. (2023). Gene therapy for inherited retinal diseases: exploiting new tools in genome editing and nanotechnology. Frontiers in Ophthalmology. https://doi.org/10.3389/fopht.2023.1270561
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.